Research programme: ophthalmic anti-fungal therapeutics - Santen

Drug Profile

Research programme: ophthalmic anti-fungal therapeutics - Santen

Alternative Names: Nova 21046

Latest Information Update: 29 May 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ophthalmic infections

Most Recent Events

  • 29 May 2013 Discontinued - Preclinical for Ophthalmic infections in France (Ophthalmic)
  • 11 Oct 2011 Novagali Pharma has been acquired by Santen Pharmaceutical
  • 22 Jan 2008 Preclinical trials in Ophthalmic infections in France (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top